COVID-19 Alberta statistics

Highlights

486
current hospitalizations

11
current ICU

5,619
total deaths ⚱

58
newly reported cases, yesterday

9.17%
percent positivity, 7-day average

79 years
average age at death ⚱

Total Cases

Figure 1: COVID-19 cases in Alberta by day and case status. Probable cases include cases where the lab confirmation is pending. Cases are under investigation and numbers may fluctuate as cases are resolved. Data included up to end of day March 13, 2023.

Characteristics

Table 1. COVID-19 cases in Alberta by age group and gender

	Gender
	Female		Male		Unknown		All
Age	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Under 1 year	2,457	0	2,939	0	2	0	5,398	1
1-4 years	10,495	2	11,418	2	7	0	21,920	3
5-9 years	15,038	2	16,789	3	4	0	31,831	5
10-19 years	34,819	6	34,883	6	37	0	69,739	11
20-29 years	56,431	9	47,368	8	62	0	103,861	16
30-39 years	65,191	10	53,943	9	29	0	119,163	19
40-49 years	54,078	9	45,092	7	16	0	99,186	16
50-59 years	38,266	6	33,915	5	11	0	72,192	11
60-69 years	22,900	4	22,767	4	6	0	45,673	7
70-79 years	12,780	2	12,840	2	2	0	25,622	4
80+ years	21,592	3	13,439	2	30	0	35,061	6
Unknown	1	0	1	0	0	0	2	0
All	334,048	53	295,394	47	206	0	629,648	100

Figure 2: COVID-19 cases in Alberta by age group. First and second panels display counts (7-day rolling average) and rate per 100,000 (7-day rolling average), respectively.

Vaccinations

Vaccine Effectiveness

Overview

A large body of evidence suggests that vaccines are safe and effective against COVID-19.
All viruses evolve over time through genetic variations. These changes can cause the emergence of new “variants” of the original virus and may have different properties than the original virus, such as increased transmissibility or the ability to cause more severe disease. Omicron, along with its sub-variants, is the currently circulating variant of concern (VOC) in Alberta.
Omicron has demonstrated increased transmissibility and capacity to evade the body’s immune response compared to previous versions of the virus. This occurs whether this immunity was generated by infection, vaccines, or both.
The protection that vaccines provide against severe disease continues to be strong even many months after immunization. Two doses of a COVID vaccine dramatically reduce the risk of hospitalization or death, and a third dose will offer even more protection. A booster dose is recommended at 5 months after the second dose, and at least 3 months following infection with COVID-19, to increase the level of protection against severe outcomes.
COVID vaccines are not always able to provide protection against infection by Omicron or one of its subvariants. Immunity against infection wanes over time, but can be boosted with an another dose of an mRNA vaccine.
Booster doses are most important for those at high risk of severe outcomes. For considerations on these doses, see https://www.alberta.ca/covid19-vaccine.aspx

The Evidence

A systematic review of the evidence published between December 2021 and April 2022 in The Lancet Infectious Diseases found that the VE of a primary series (for most people, this is two doses) against severe outcomes remained high and stable over time at over 80%. ^{[1, 2]} VE against infection by Omicron was lower than for previous variants and waned over time with most protection against infection lost by 4-6 months post second dose. However, boosting with a third dose increased the VE against infection with Omicron (to about 60%) and against severe outcomes (to 90%). ^{[1, 2]}

The figure on page 20 of this document helps to illustrate the results from the evidence, for both the primary series as well as for a booster dose.
Another evidence review, published by McMaster University on June 22, 2022, also examined the effectiveness of COVID-19 vaccines against the Omicron variant. It found that in general, people with a primary series continue to have a good level of protection against hospitalisation and death due to COVID-19 for 7 to 8 months after being vaccinated. A third (booster) dose increases this protection against COVID-19 related hospitalisations, with a very minimal degree of waning after several months. ^[3]

In addition to reviews that assess the VE of second and third doses, there is emerging evidence on the benefit of a fourth dose. A recently published study in healthcare workers from Israel found that only 7% of those with a fourth dose became infected with Omicron, versus 20% of those with only three doses, demonstrating increased protection against infection. Infections were either asymptomatic or mild and no severe outcomes were seen. ^[4]

Note that this data is current up to August 5, 2022 and will be updated periodically as new information emerges.

References

Higdon, MM, et al. 2022. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. The Lancet Infectious Diseases. Published online June 22, 2022. Accessed at: https://doi.org/10.1016/S1473-3099(22)00409-1
Higdon MM, Baidya A, Walter KK, et al. Supplement to: Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. The Lancet Infectious Diseases. Published online June 22. Accessed at https://www.thelancet.com/cms/10.1016/S1473-3099(22)00409-1/attachment/3ba9ad38-48b8-46a3-a993-baddc6bf8bbd/mmc1.pdf
Bacon, SL, et al. 2022. COVID-19 living evidence synthesis #10 (version 10.7): What is the long-term effectiveness of available COVID-19 vaccines for adults, including for variants of concern and over time frames beyond 112 days in those with a primary series and beyond 84 days in those with a primary series and an additional dose? The Montreal Behavioural Medicine Centre, META group. Published online June 22, 2022. Accessed at: https://www.mcmasterforum.org/docs/default-source/product-documents/living-evidence-syntheses/covid-19-living-evidence-synthesis-10.7---what-is-the-long-term-effectiveness-of-available-covid-19-vaccines-for-adults.pdf?sfvrsn=4c92f905_5
Cohen MJ et al. 2022. Association of receiving a fourth dose of the BNT162b Vaccine with SARS-CoV-2 infection among health care workers in Israel. JAMA Netw Open. 5(8):e2224657. Published online August 2, 2022. Accessed at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794864

Outbreaks

Table 2. Summary of open COVID-19 outbreaks in Alberta.

Facility Type	Calgary	Central	Edmonton	North	South	Total
Supportive Living/Home Living Sites	6	3	8	6	1	24
Long Term Care Facility	6	2	2	3	0	13
Acute Care Facility	0	1	6	1	1	9
Other	0	1	1	0	0	2
Total	12	7	17	10	2	48

Figure 3: Number of outbreaks by week opened.

Severe Outcomes

Table 3. Total Hospitalizations, ICU admissions and deaths (ever) among COVID-19 cases in Alberta by age group

Age Group	Cases	Hospitalized			ICU			Deaths
	Count	Count	Case rate	Pop. rate	Count	Case rate	Pop. rate	Count	Case rate	Pop. rate
Total	629648	34578	5.5	782.9	4698	0.7	106.4	5619	0.9	127.2
Under 1 year	5398	598	11.1	1184.7	95	1.8	188.2	0	0.0	0.0
1-4 years	21920	510	2.3	234.9	52	0.2	24.0	1	0.0	0.5
5-9 years	31831	245	0.8	88.3	34	0.1	12.3	2	0.0	0.7
10-19 years	69739	598	0.9	112.3	75	0.1	14.1	2	0.0	0.4
20-29 years	103861	1706	1.6	288.9	181	0.2	30.6	25	0.0	4.2
30-39 years	119163	2794	2.3	391.0	346	0.3	48.4	50	0.0	7.0
40-49 years	99186	2970	3.0	488.6	586	0.6	96.4	120	0.1	19.7
50-59 years	72192	4279	5.9	777.2	968	1.3	175.8	312	0.4	56.7
60-69 years	45673	5751	12.6	1213.4	1231	2.7	259.7	744	1.6	157.0
70-79 years	25622	6476	25.3	2483.6	862	3.4	330.6	1309	5.1	502.0
80+ years	35061	8651	24.7	6145.3	268	0.8	190.4	3054	8.7	2169.4
Unknown	2	0	0.0	NA	0	0.0	NA	0	0.0	NA
Note:
Based on total hospitalizations and ICU admissions ever.
Row percent is out of the number of cases in each age group.
Each ICU admission is also included in the total number of hospitalization
Case rate (per 100 cases)
Population rate (per 100,000 population)

Figure 4: Number of COVID-19 cases currently in hospital (ICU and non-ICU) with a primary or contributing cause due to COVID-19. Please note, information on reason for hospitalization was unavailable prior to 2022-02-01 and is delayed by approximately one week from a hospitalization event.

Figure 5: Number of current COVID-19 cases in hospital (ICU and non-ICU)

Figure 6: Rate of new hospitalizations related to COVID-19 (7-day rolling average, average of current day and previous 6 days) by admission date in Alberta and by zone. Please note, information on reason for hospitalization was unavailable prior to 2022-02-01 and is delayed by approximately one week from a hospitalization event.

Figure 7: Rate of new hospitalizations (7-day rolling average, average of current day and previous 6 days) by admission date in Alberta and by zone

Figure 8: Daily COVID-19 attributed deaths. Data are subject to change; when death date is unavailable the date reported to Alberta Health is used until a death date is known.

Geospatial

Figure 9: Cumulative COVID-19 cases in Alberta by zone and date reported to Alberta Health. Cases without a postal code or incorrect postal codes are labelled as unknown.

Geography presented by Alberta Health Services Zones. Cases without a postal code or incorrect postal codes are not included. Standard scores are calculated to compare the 7-day case rate of each Zone to the provincial average. Scores are separated into 3 categories, with -1 to 1 being close to the provincial average, >1 being higher than average, and < -1 being lower than the provincial average.

Laboratory Testing

Figure 10: Tests performed for COVID-19 in Alberta by day. Tests can be performed for the same person multiple times.

Notifications

Popular topics: